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Heme oxygenases (HO-1; HO-2) catalyze conversion of heme to free iron, carbon monoxide, and biliverdin/bilirubin. To
determine the eﬀects of renal HO-1 induction on blood pressure and renal function, normal control rats (n = 7) and hemin-
treated rats (n = 6) were studied. Renal clearance studies were performed on anesthetized rats to assess renal function; renal
blood ﬂow (RBF) was measured using a transonic ﬂow probe placed around the left renal artery. Hemin treatment signiﬁcantly
induced renal HO-1. Mean arterial pressure and heart rate were not diﬀerent (115 ±5mmHg versus 112 ±4mmHg and 331 ±16
versus 346 ± 10bpm). However, RBF was signiﬁcantly higher (9.1 ± 0.8v e r s u s7 .0 ± 0.5mL/min/g, P<0.05), and renal vascular
resistance was signiﬁcantly lower (13.0 ± 0.9v e r s u s1 6 .6 ± 1.4 [mmHg/(mL/min/g)], P<0.05). Likewise, glomerular ﬁltration
rate was signiﬁcantly elevated (1.4 ± 0.2v e r s u s1 .0 ± 0.1mL/min/g, P<0.05), and urine ﬂow and sodium excretion were also
higher (18.9 ± 3.9v e r s u s8 .2 ± 1.0μL/min/g, P<0.05 and 1.9 ± 0.6v e r s u s0 .2 ± 0.1μmol/min/g, P<0.05, resp.). The plateau
of the autoregulation relationship was elevated, and renal vascular responses to acute angiotensin II infusion were attenuated in
hemin-treated rats reﬂecting the vasodilatory eﬀect of HO-1 induction. We conclude that renal HO-1 induction augments renal
function which may contribute to the antihypertensive eﬀects of HO-1 induction observed in hypertension models.
1.Introduction
Heme metabolism is catalyzed by heme oxygenases (HO),
which convert heme to carbon monoxide (CO), biliverdin,
and free iron [1]. Two isoforms of HO are expressed in the
kidney, HO-1 and HO-2 [2, 3]. The kidney has relatively
low basal level of HO activity [2, 4] that is mainly derived
from the constitutive HO-2 [5–7]. Renal HO-2 is localized to
epithelial cells of the proximal tubule, thick ascending limb
and distal tubule, connecting tubule, and principal cells of
thecollectingducts[8].RenalHO-1isinducedundercertain
pathological conditions and in response to several agents [3,
9–11]. The pattern of HO-1 expression in the kidney varies
with diﬀerent inducers utilized [2, 12]. Acute treatment with
hemin increases renal cortical dialysate CO concentration
and causes diuresis and natriuresis [13]. Increases in renal
perfusion pressure (RPP) induce renal CO production, and
HO inhibition prevents the pressure-dependent increase in
CO and attenuates pressure natriuresis [14]. This suggests
thatinductionofHO-1couldmodulaterenalhemodynamics
and renal excretory function.
HO inhibition during nitric oxide synthesis inhibition
constricts aﬀerent arterioles (Aﬀ-Art) [15], and exogenous
CO administration dilates renal Aﬀ-Art from normal rats
[15, 16]. Furthermore, endogenously produced CO exerts
a vasodilatory inﬂuence on the renal circulation, and inhi-
bition of HO decreases renal blood ﬂow (RBF) [17–21].
Bilirubin is also produced from heme metabolism by HO
and biliverdin reductase and is an abundant endogenous
antioxidant [22]. Bilirubin scavenges reactive oxygen species
[23–25] and inhibits angiotensin II-mediated activation of
NADPH oxidase [26, 27], eﬀects that also potentially cause
dilation of the renal microvasculature. Chronic treatment of
angiotensin-II-infused hypertensive rats with bilirubin2 International Journal of Hypertension
attenuates urinary protein excretion [28], and inhibition of
bilirubin metabolism attenuates angiotensin II-dependent
hypertension in mice [29]. Upregulation of renal HO-1
increases CO and biliverdin/bilirubin production, reduces
NADPH oxidase-mediated oxidative stress [26], inhibits cor-
tical 20-HETE synthesis [30], and inhibits thromboxane syn-
thase [31]. Overexpression of HO-1 reduces the pressor res-
ponsivenesstoangiotensinII[32],andinhibitionofHOacti-
vity magniﬁes the renal vasoconstrictor eﬀect of angiotensin
II and enhances pressure-induced constriction of isolated
pressurized renal interlobular arteries [20]. These results im-
plicate HO-derived metabolites as important modulators of
renal microcirculatory function. However, recent data indi-
cate that blood pressure and RBF responses to increased
angiotensin II or inhibition of nitric oxide are not signiﬁ-
cantly enhanced in HO-2 knockout mice [33].
This study was designed to examine the hypothesis that
renal HO-1 induction augments renal hemodynamics and
renal excretory function. To test this hypothesis, we per-
formed renal clearance and renal hemodynamic studies on
control and hemin-treated rats. Accordingly, the aims of this
study were (1) to determine the eﬀects of HO-1 induction
on renal blood ﬂow (RBF), glomerular ﬁltration rate (GFR),
and renal excretory function and (2) to determine the eﬀects
of HO-1 induction on RBF autoregulatory responses to
changes in RPP and on the renal vasoconstrictor responses
to angiotensin II.
2. Methods
2.1. Animal Treatment. All experimental protocols were ap-
proved by Tulane Institutional Animal Care and Use Com-
mittee. Male Sprague Dawley rats weighing 300–400g were
fed a normal rat diet (TD 90229, Harlan-Teklad) with free
access to water. Two groups of rats were studied: (1) con-
trol rats and (2) Hemin-treated rats which received 4 i.p.
injections of hemin for 4 consecutive days (3mg/100g Bwt./
day) prior to the acute experiment.
2.2. Renal Function Studies. As described by Patterson et al.
[34] and Wang et al. [35], on the day of acute experiment,
ratswereanesthetizedwithinactin(thiobutabarbitalsodium,
Sigma, Saint Louis, USA, 100mg/kg, i.p.) and placed on
thermostatically controlled heated surgical table to maintain
rectal temperature at 37◦C .Ap o l y e t h y l e n et u b ew a sp l a c e d
in the trachea and the animals were allowed to breathe air
enriched with oxygen (95% O2/5% CO2). The left carotid
arterywascannulatedtoallowcontinuousmonitoringofsys-
temic arterial blood pressure and heart rate. The left femoral
vein was cannulated to allow infusion of solutions. The left
kidney was exposed from a ﬂank incision, gently freed, and
placedinaplastic cup.Fortimedurine collections,acatheter
was introduced into the ureter and passed to the pelvis.
The renal artery was separated carefully from the renal vein
which enabled placement of a noncannulating ﬂow probe,
1mm in the diameter, connected with a Transonic ﬂowmeter
(Transonic System Inc., Ithaca, NY, USA) for measurement
of the total RBF. During surgery, an isotonic saline solution
containing albumin (6g/dL) was infused at 1.2mL/h (for
300g body weight). Following the surgical procedures, an
isotonic saline solution containing 1% albumin and 7.5%
polyfructosan (Inutest, Fresenius Kabi, Austria) was infused;
initially a priming dose was infused at the rate of 1.6mL/kg
for 5min followed by a continuous infusion at 1.2mL/h and
a stabilization period of about 1h was allowed.
2.2.1. Experimental Protocol
Protocol 1. experiments were performed to determine the
eﬀects of HO-1 induction with hemin on renal hemody-
namics and renal excretory function. After the stabilization
period, at least six 15-minute collection periods were initi-
ated during which measurements of mean arterial pressure
(MAP), heart rate (HR), RBF, renal vascular resistance
(RVR), GFR, urine ﬂow (UV), and urinary sodium excretion
(UNaV) were averaged. Measurements for all collection
periods were then averaged. The data from control and
hemin-treated rats were compared.
Protocol 2. these experiments were done to determine the
eﬀectsofHO-1inductionwithheminonRBFautoregulatory
responses. An aortic clamp was placed above the junction
of the left renal artery to regulate RPP to the left kidney.
The left femoral artery was cannulated, and the catheter was
advanced up the aorta to measure RPP at the left kidney. A
Transonic ﬂow probe placed around the left renal artery was
used to measure changes in RBF in response to decreases in
RPP.Afterthestabilizationperiod,RPPwasdecreasedto110,
100, 90, and 80mmHg and was maintained for 5 minutes at
each level. MAP, HR, RBF, and RPP were averaged for each
time period at diﬀerent RPP.
Protocol 3. these experiments were done to determine the
eﬀects of HO-1 induction with hemin on renal vascular
responses to angiotensin II. After the stabilization period,
MAP and RBF were measured during i.v. infusion of
vehicle followed by angiotensin II (Ang II 50, 100, and
200ng/kg/min). Each infusion period lasted 30 minutes, and
RBF responses were averaged during the last 20 minutes.
2.3.AnalyticalProceduresandHeminPreparation. Urinevol-
umes were determined gravimetrically. Blood samples were
collected in heparinized tubes and centrifuged at 2500g for
10min at 4◦C to separate the plasma, which was stored at
−20◦C. Plasma and urine sodium concentrations were mea-
sured by ﬂame photometry. Polyfructosan concentrations in
urine and plasma samples were measured by standard spec-
trophotometry. GFR was determined from the clearance of
polyfructosan.
Hemin (Sigma-Aldrich, St. Louis, MO): 50mg hemin
was dissolved in 1mL of 0.1M NaOH; this solution was dilu-
ted using deionized water and pH was adjusted to 7.8; the
ﬁnal volume was adjusted to 5mL.
2.3.1. Tissue Preparation. Left kidneys were immediately col-
lected and frozen at −80◦C until used for Western blot.International Journal of Hypertension 3
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Figure 1: Western blot and densitometry analysis showing the eﬀect of treatment with Hemin (3mg/100g body wt/day for 4 days) on renal
HO-1 and HO-2 protein expression (n = 6) compared to control rats (n = 6). Results are normalized by β-actin and expressed as folds of
control and presented as mean ± SE for each group, ∗P<0.05 versus Control.
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Figure 2: Renal blood ﬂow (RBF), renal vascular resistance (RVR), and glomerular ﬁltration rate (GFR) in hemin-treated rats (n = 6)
compared to control rats (n = 7). Results are expressed as mean ± SE for each group, ∗P<0.05 versus Control.
Tissues were homogenized in buﬀer at pH 7.4, containing
0.25M sucrose. The homogenates were centrifuged in an Ep-
pendorf centrifuge at 10,000g for 10min at 4◦Ct or e m o v e
unbroken cells and the supernatant was stored at −80◦C.
Protein concentration was determined according to the
method of Bradford (BioRad, Hercules, CA) [36].
2.3.2. Western Blot Analysis. As previously described [30],
cell-free homogenates (10,000×g supernatant) of kidney
preparations were separated by SDS/polyacrylamide gel elec-
trophoresis and transferred to a hydrophobic polyvinylid-
ene diﬂuoride (PVDF) transfer membrane (Amersham-GE
Biosciences,Piscataway,NJ).Themembraneswereincubated4 International Journal of Hypertension
Table 1: Hemodynamics and renal excretory measurements in hemin-treated rats compared to control untreated rats.
Control (n = 7) Hemin (n = 6)
Mean arterial pressure, MAP (mmHg) 112 ± 4 115 ± 5
Heart rate, HR (bpm) 346 ± 10 331 ± 16
Glomerular ﬁltration rate, GFR (mL/min/g) 1.0 ±0.11 .4 ±0.2∗
Renal blood ﬂow, RBF (mL/min/gm) 7.0 ±0.59 .1 ±0.8∗
Renal vascular resistance, RVR [mmHg/(mL/min/g)] 16.6 ±1.41 3 .0 ±0.9∗
Urine ﬂow, UV (μL/min/g) 8.2 ±1.01 8 .9 ±3.9∗
Sodium excretion, UNaV( μmol/min/g) 0.2 ±0.11 .9 ±0.6∗
∗P<0.05 versus control.
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Figure 3: Urine ﬂow (UV) and urinary sodium excretion (UNaV) in hemin-treated rats (n = 6) compared to control rats (n = 7). Results
are expressed as mean ± SE for each group, ∗P<0.05 versus Control.
with Odyssey blocking reagent (LI-COR Biosciences, Lin-
coln, Nebraska) at 4◦C overnight. The membranes were
incubated for 1hr with one of the following antibodies: rab-
bit anti-rat HO-1 and HO-2 polyclonal antibodies (1:1000,
Stressgen Biotechnologies Corp, Victoria, BC, Canada) or
mouse anti-β-actin monoclonal antibody. The membranes
were washed with phosphate buﬀered saline tween-20
(PBST) and subsequently probed with ﬂuorescent tagged
secondaryantibodiesatadilutionof1:15000.Thesignalwas
detected using Odyssey ﬂuorescent scanner.
2.4. Statistical Analysis. Results are presented as mean ± SE
for a number (n) of experiments. Unpaired t-test was used
to analyze diﬀerences in basal measurements, and HO-1
and HO-2 protein expression between the control and
hemin-treated groups. Repeated measures one-way ANOVA
followed by Bonferroni’s multiple comparison test was used
to analyze changes within the same group. Repeated mea-
sures two-way ANOVA followed by Bonferroni’s multiple
comparison test was used to analyze diﬀerences between
groups. P<0.05 was considered statistically signiﬁcant.
3. Results
3.1. HO-1 Protein Expression Is Induced in Kidneys from
Hemin-Treated Rats. HO-1 protein expression signiﬁcantly
increased by 4.0 ± 1.3-fold in kidneys from hemin-treated
rats compared to kidneys from normal control rats (n = 6,
P<0.05)(Figure 1).NodiﬀerencesinrenalHO-2expression
between hemin-treated rats and normal control rats were
detected (Figure 1).
3.2.RenalHO-1InductionwithHeminIsAssociatedwithAug-
mented Renal Hemodynamics and Excretory Function withoutInternational Journal of Hypertension 5
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Figure 4: Renal blood ﬂow (RBF) autoregulatory responses to changes in renal perfusion pressure (RPP) in hemin-treated rats (n = 4)
compared to control rats (n = 7). Results are expressed as mean ± SE for each group, ∗P<0.05 versus Control.
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Figure 5: Changes in RBF and RVR in response to infusion of angiotensin II in hemin-treated rats (n = 5) compared to control rats (n = 7).
Results are expressed as mean ± SE for each group, ∗P<0.05 versus Control, #P<0.05 versus baseline before angiotensin II infusion.
Alteration in Mean Arterial Pressure or Heart Rate. HR and
MAP were not signiﬁcantly diﬀerent in hemin-treated rats
compared to control rats (Table 1).WhileRBFandGFRwere
signiﬁcantly higher, RVR was signiﬁcantly lower in hemin-
treated rats (Table 1 and Figure 2). These data indicate that
renal HO-1induction is associated with renal vasodilation in
hemin-treated rats.
Hemin-treatedratsalsohadincreasedurineﬂowanduri-
nary sodium excretion (UNaV) indicating that renal HO-1
induction is associated with augmented renal excretory fun-
ction (Table 1 and Figure 3).
3.3. Hemin-Treatment Increases the RBF Autoregulatory
Plateau in Response to Decreases in RPP. Figure 4(a) shows
that RBF was signiﬁcantly higher in hemin-treated rats com-
pared to control rats at all measured RPP points indicating
that the vasodilatory eﬀect is maintained at diﬀerent renal6 International Journal of Hypertension
perfusion pressures. Figure 4(b) demonstrates that RBF
autoregulatory responses to changes in RPP were not altered
in hemin-treated rats indicating that renal autoregulatory
responses are maintained with a tendency to show improved
autoregulatory capability.
3.4. Renal HO-1 Induction with Hemin Is Associated with
Attenuated Renal Vasoconstrictor Responses to Ang II and
Maintained Pressor Responses. Basal MAP was not signiﬁ-
cantly diﬀerent between control and hemin treated rats
(126.0±2.1mmHg, n = 7 versus 118.9±3.9mmHg, n = 5).
RBF was signiﬁcantly higher in hemin treated rats compared
t oc o n t r o lr a t s( 1 0 .5 ± 0.7mL/min/g, n = 5v e r s u s8 .1 ±
0.9mL/min/g, n = 7, P<0.05).
In response to angiotensin II infusion, MAP signiﬁcantly
increased to the same extent in both groups. In response
to infusion with Ang II 50, 100, and 200ng/kg/min, MAP
increased from 126.0 ± 2.1mmHg to 134.9 ± 1.7, 142.7 ±
1.6, and 150.7 ± 2.2mmHg in the control group (n =
7) and from 118.9 ± 3.9 to 131.4 ± 7.2, 136.9 ± 9.3, and
142.7 ± 9.7mmHg in the hemin-treated rats (n = 5). RBF
signiﬁcantlydecreasedinresponsetoinfusionwithAngII50,
100, and 200ng/min/kg in both groups; however, RBF was
signiﬁcantly higher in the hemin-treated group compared to
the control group (P<0.0001). RBF during infusion with
200ng/min/kg Ang II was 7.7 ± 0.6mL/min/g in hemin-
treated group (n = 5) compared to 5.1 ± 0.6mL/min/g
in control group (n = 7) (Figure 5). The reduced respon-
siveness to Ang II infusion in the hemin treated group is
shown by the attenuated increases in RVR with the Ang II
infusions.
4. Discussion
HO-1 plays a major renoprotective role when induced under
certain pathophysiological conditions [4, 9, 17, 19]. Al-
though several reports examined eﬀects of acute activation
or inhibition of HO via acute administration of the substrate
hemin or HO inhibitors, the eﬀects of chronic induction of
HO-1 on renal hemodynamics and renal excretory function
have not been examined before. To determine the eﬀects of
HO-1 on renal function, hemin was used to induce HO-1
expression [1]. Hemin increases HO activity via increasing
substrate availability and also by transcriptional activation
of hmox-1 gene [37]. Treating with HO-1 inducers causes
diﬀerential induction of HO-1 in the kidney; increased
expression of HO-1 in diﬀerent renal structures may exert
diﬀerent eﬀects on renal function [38]. As expected, in our
study chronic hemin administration increased HO-1 expres-
sion whereas it did not aﬀect HO-2 expression.
In rats treated with hemin, MAP was not diﬀerent com-
pared to untreated rats; however, hemin-treated rats had sig-
niﬁcantly higher RBF and lower RVR. These results indicate
that renal HO-1 induction exerts a renal vasodilatory eﬀect.
This is consistent with previously reported data that acute
heme administration increases RBF, urine ﬂow, and sodium
excretion [13]. In addition, hemin-treated rats had signiﬁ-
cantly higher GFR compared to control rats indicating that
the vasodilatory response is mediated through dilation of
renal arterioles. These data are consistent with previous
reports showing that acute inhibition of HO decreases RBF
[18, 20] and infusion of CO increased RBF and GFR. In
addition, CO causes vasodilation of aﬀerent arterioles [15].
Interestingly, this renal vasodilatory response in hemin-
treated rats was associated with signiﬁcantly higher urine
ﬂow (2-fold) and sodium excretion (10-fold) (Figure 3),
indicating that HO-1 induction exerts diuretic and natri-
uretic responses. This is consistent with previous data
showing that acute heme administration causes natriuresis
[13], while acute HO inhibition decreases urine ﬂow and
sodium excretion [39]. With chronic treatment, induction
of HO-1 may be in diﬀerent segments of the nephron
and may be inhibiting other ion transporters; however, the
eﬀects of HO products on tubular transporters have not
beenwellcharacterized.Inaddition,previousresearchshows
that acute inhibition of HO with CrMP attenuates pressure-
natriuresis, indicating that HO participates in the natriuretic
response to increases in arterial pressure [14]. We speculate
that the eﬀects of chronic HO-1 induction on renal function
are mediated directly via increases in CO and/or bilirubin
production. However, indirect eﬀects via regulation of other
hemeenzymesand/or renaltransporterscannotbeexcluded.
To determine the eﬀect of this vasodilatory response on
renal autoregulatory capability, renal perfusion pressure was
decreased using an aortic clamp and the corresponding RBF
was recorded. Data presented in Figure 4 indicate that renal
autoregulatory responses are maintained in hemin-treated
rats albeit at higher RBF and changes in RBF in response
to decreases in RPP were comparable in hemin-treated and
control rats. This indicates that the renal vascular responses
to changes in RPP are maintained; however, the plateau
of the autoregulation relationship is elevated reﬂecting the
vasodilatory eﬀect of HO-1 induction. This may protect the
kidney from excessive vasoconstriction during hypertension
while limiting the deleterious eﬀects of the increases in renal
perfusion pressure, which could explain the renoprotective
role of HO induction in diﬀerent models of hypertension
[38]. To examine this hypothesis, changes in RBF in response
to acute infusion of angiotensin II were compared between
hemin-treated and control untreated rat.
Angiotensin II infusion increased MAP to the same
level in hemin-treated rats and control rats; however, renal
vasoconstrictor responses were signiﬁcantly attenuated in
hemin-treated rats (Figure 5). This observation is consistent
with previous data showing that the inhibition of HO
with SnMP magniﬁes the renal vasoconstrictor eﬀect of
angiotensin II [20]. Although RBF signiﬁcantly decreased
in both control and hemin-treated rats, the increase in
RVR in response to angiotensin II was signiﬁcantly greater
in control rats than in hemin-treated rats (Figure 5). This
ﬁnding is of signiﬁcant importance because induction of
HO-1 by heme administration to angiotensin-II-infused
hypertensiveratsincreasescreatinineclearanceanddecreases
proteinuria [17], indicating a renoprotective eﬀect of HO-
1 during angiotensin II hypertension. In addition, chronic
hemin infusions normalize blood pressure in spontaneouslyInternational Journal of Hypertension 7
hypertensive rats [40] and induction of HO-1 prevents the
blood pressure increase in angiotensin-II-infused mice [41].
In summary, the present study demonstrates that phar-
macological renal HO-1 induction increases RBF, GFR,
urine ﬂow, and sodium excretion; these eﬀects are con-
ducive to renoprotection. Renal autoregulatory responses
are maintained but operate at a higher RBF during HO-1
induction. Finally, renal HO-1 induction with hemin signif-
icantly attenuates renal vasoconstrictor responses to angio-
tensin II. Under several pathophysiological conditions, HO-
1 is induced in the kidney [9]; renal HO-1 induction under
these circumstances might play a renoprotective role by
attenuating excessive renal vasoconstrictor responses.
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